Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated:  1/27/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated: 1/27/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated:  1/27/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated: 1/27/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated:  1/27/2016
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.
Status: Enrolling
Updated: 1/27/2016
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release
Status: Enrolling
Updated:  1/27/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release
Status: Enrolling
Updated: 1/27/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Tivozanib As Maintenance Therapy In GYN
A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  1/27/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Tivozanib As Maintenance Therapy In GYN
A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 1/27/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
21st Century Oncology - Carolina Regional Cancer Center
mi
from
Myrtle Beach, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
21st Century Oncology - Carolina Regional Cancer Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Abington Memorial Hospital
mi
from
Abington, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
AnMedical Health Cancer Center
mi
from
Anderson, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Arizona Cancer Center
mi
from
Scottsdale, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Arizona Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Cancer Care Northwest
mi
from
Spokane, WA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
CaroMont Health Comprehensive Cancer Center
mi
from
Gastonia, NC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
CaroMont Health Comprehensive Cancer Center
mi
from
Gastonia, NC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Columbia - St. Mary's
mi
from
Milwaukee, WI
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Columbia - St. Mary's
mi
from
Milwaukee, WI
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Hughes Cancer Center
mi
from
East Stroudsburg, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Hughes Cancer Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Ironwood Cancer and Research Centers
mi
from
Mesa, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Ironwood Cancer and Research Centers
mi
from
Mesa, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
John B. Amos Cancer Center
mi
from
Columbus, GA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
John B. Amos Cancer Center
mi
from
Columbus, GA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Mayo Clinic - LaCrosse
mi
from
LaCrosse, WI
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Mayo Clinic - LaCrosse
mi
from
LaCrosse, WI
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Mount Nittany Medical Center
mi
from
State College, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Norwalk Hospital
mi
from
Norwalk, CT
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Parkview Research Center
mi
from
Fort Wayne, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Radiation Oncology Associates - Parkview Research Center
mi
from
Fort Wayne, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Radiation Oncology Associates - Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Sanford Health
mi
from
Bismarck, ND
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Sanford Health
mi
from
Bismarck, ND
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Sanford Research/USD
mi
from
Sioux Falls, SD
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Sanford Research/USD
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. John Health System
mi
from
Tulsa, OK
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. John Health System
mi
from
Tulsa, OK
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. Vincent Anderson Regional Hospital Cancer Center
mi
from
Anderson, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. Vincent Anderson Regional Hospital Cancer Center
mi
from
Anderson, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Colorado Hospital, Dept. of Radiation Oncology
mi
from
Aurora, CO
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Colorado Hospital, Dept. of Radiation Oncology
mi
from
Aurora, CO
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Willis Knighton Cancer Center
mi
from
Shreveport, LA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Willis Knighton Cancer Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Smoking Status and Body Image in Oral Cancer Patients
A Prospective Examination of Smoking Status and Body Image in Surgical Patients With Cancer of the Oral Cavity
Status: Enrolling
Updated:  1/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Smoking Status and Body Image in Oral Cancer Patients
A Prospective Examination of Smoking Status and Body Image in Surgical Patients With Cancer of the Oral Cavity
Status: Enrolling
Updated: 1/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Lebanon, NH
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Greensville, SC
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Greensville, SC
Click here to add this to my saved trials
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
San Antonio, TX
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Prevention of Ovarian Cancer in Women Participating in Mammography
Prevention of Ovarian Cancer in Women Participating in Mammography
Status: Enrolling
Updated:  1/27/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Prevention of Ovarian Cancer in Women Participating in Mammography
Prevention of Ovarian Cancer in Women Participating in Mammography
Status: Enrolling
Updated: 1/27/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  1/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 1/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  1/28/2016
UCLA Hematology-Oncology
mi
from
Santa Monica, CA
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 1/28/2016
UCLA Hematology-Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  1/28/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 1/28/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/28/2016
H. Lee Moffitt Cancer Center (NSCLC)
mi
from
Tampa, FL
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/28/2016
H. Lee Moffitt Cancer Center (NSCLC)
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy
A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated:  1/28/2016
University of Wisconsin
mi
from
Madison, WI
Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy
A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated: 1/28/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Providence Hospital,
mi
from
Mobile, AL
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Providence Alaska Medical Center
mi
from
Anchorage, AK
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Saint Bernards Regional Medical Center
mi
from
Jonesboro, AR
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Saint Bernards Regional Medical Center
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated:  1/28/2016
Mills - Peninsula Hospitals
mi
from
Burlingame, CA
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Enrolling
Updated: 1/28/2016
Mills - Peninsula Hospitals
mi
from
Burlingame, CA
Click here to add this to my saved trials